Condensed Consolidated Statements of Cash Flows - USD ($) shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating activities
Net loss	$ (217,310)	$ (143,045)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	29,126	23,879
Depreciation and amortization	1,180	1,341
Non-cash accretion of other current liability	2,966
Non-cash interest expense	12,190	9,342
Non-cash accretion & amortization of short-term investments	(6,027)
Non-cash rent expense	289	294
Change in fair value of embedded derivative liability	(1,300)	(150)
Gain on settlement of forward contract	(8,900)
Acquired IPR&D assets classified as investing activities	92,385	5,667
Changes in operating assets and liabilities:
Accounts receivable	(4,439)	(8,317)
Inventory	(5,271)	(4,845)
Prepaid expenses and other current assets	181	(2,367)
Deferred revenue		(148)
Other long-term assets, net	3,157	1,660
Accounts payable, accrued expenses and other liabilities	6,739	9,915
Net cash used in operating activities	(95,034)	(106,774)
Investing activities
Purchases of short-term investments	(201,935)	(314,265)
Maturities of short-term investments	173,105	291,675
Acquisition of IPR&D assets	(40,500)	(5,667)
Purchases of property and equipment		(48)
Net cash used in investing activities	(69,330)	(28,305)
Financing activities
Repayment of deferred royalty obligation	(9,092)	(4,824)
Proceeds from the exercise of stock options	12,986	2,471
Proceeds from issuance of common stock from ESPP	1,270	1,053
Net proceeds from issuance of common stock		48,875
Proceeds from royalty financing agreement, net of issuance costs		24,370
Gain on settlement of forward contract	8,900
Proceeds from Series A Preferred Stock, net of issuance costs	138,850
Net cash provided by (used in) financing activities	152,914	71,945
Effect of exchange rates on cash	(975)	50
Net increase (decrease) in cash, cash equivalents and restricted cash	(12,426)	(63,084)
Cash, cash equivalents and restricted cash at beginning of period	60,409	128,005
Cash, cash equivalents and restricted cash at end of period	47,983	$ 64,921
Supplemental disclosure of non-cash investing and financing activities:
Non-current liability issued in exchange for the acquisition of IPR&D	$ 33,669
Issuance of common stock in exchange for IPR&D	18,716
Accretion of preferred stock dividends	$ 2,631